Bioequivalence Study of Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets Under Fed Conditions

• ClinicalTrials.gov Identifier: NCT01132222
• Recruitment Status: Completed
• First Posted: May 27, 2010
• Last Update Posted: June 14, 2010
• Sponsor: Dr. Reddy's Laboratories Limited
• Information provided by: Dr. Reddy's Laboratories Limited

Study Description

Brief Summary:

The purpose of this study is to assess the bioequivalence of Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg under fed conditions.

Condition or disease	Intervention/treatment	Phase
Healthy	Drug: Ibuprofen + Pseudoephedrine Hydrochloride	Phase 1

Detailed Description:

This study assess the bioequivalence of Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets of Dr. Reddy's and Advil® Cold and Sinus Caplets of Wyeth Consumer Healthcare in healthy human adult subjects with the single oral administration under fed conditions with a washout period of 7 days.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 34 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Randomized, Open Label, 2-treatment, Single Dose, Crossover, Bioequivalence Study of Ibuprofen 200 mg+Pseudoephedrine HCL 30 mg Tablets of Dr. Reddy's and Advil® Cold and Sinus Caplets of Wyeth Consumer Healthcare Under Fed Conditions.
• Study Start Date: September 2004
• Actual Primary Completion Date: October 2004
• Actual Study Completion Date: October 2004

Arms and Interventions

Arm	Intervention/treatment
Experimental: Ibuprofen + Psuedoephedrine Hydrochloride; Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets	Drug: Ibuprofen + Pseudoephedrine Hydrochloride; Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets; Other Name: Advil® Cold and Sinus
Active Comparator: Advil® Cold and Sinus; Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare	Drug: Ibuprofen + Pseudoephedrine Hydrochloride; Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets; Other Name: Advil® Cold and Sinus

Outcome Measures

Primary Outcome Measures :

1. Bioequivalence based on Cmax and AUC parameters [ Time Frame: 2 months ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 50 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Healthy human subjects between 18-50 years of age (inclusive), weighing as per the standard height and weight chart of Life Insurance Corporation of India (II Underweight and Overweight Min. & Max. Chart)
• Subjects who have no evidence of underlying disease during screening medical history and whose physical examination is performed within 21 days to commencement of the study.
• Subjects whose screening laboratory values are within normal limits or considered by the physician/Principal Investigator to be of no clinical significance.
• Informed consent given in written form according to section 10.3 of the protocol.

• Female Subjects:

  1. of child bearing potential practicing an acceptable method of birth control for the duration of study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.
  2. postmenopausal for at least 1 year.
  3. surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject.

Exclusion Criteria:

1. History or presence of significant:

   i. Cardiovascular, pulmonary, hepatic, renal hematological; gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.

   • Alcohol dependence, alcohol abuse or drug abuse within past one year.
   • Moderate to heavy smoking (> 10 cigarettes/day) or on assumption of tobacco products.
   • History of difficulty in swallowing.
   • Clinically significant illness within 4 weeks before the start of the study
   • Asthma, urticaria or other allergic type reactions after taking any medication.

2. Subjects who, through completion of the study, would have donated in excess of

   • 500 ml of blood in 14 days, or
   • 500 - 800 m l of blood in 14 days (unless approved by the Principal Investigator)
   • 1000 ml of blood in 90 days
   • 1250 ml of blood in 120 days
   • 1500 ml of blood in 180 days
   • 2000 ml of blood in 270 days
   • 2500 ml of blood in 1 year
3. Participation in another clinical trial within the preceding 28 days of study start.

4. Subjects who have:

   • Systolic blood pressure less than 90 mm of Hg and more than 150 mm of Hg
   • Diastolic blood pressure less than 60 m of Hg and more than 95 mm of Hg. Minor deviations (1-3 mm Hg) at check-in may be acceptable at the discretion of the physician/investigator
   • Pulse rate below 50/min. and above 105/min.
5. Female volunteers demonstrating a positive pregnancy screen or currently breast-feeding.

Contacts and Locations

Locations

India

Lotus Labs Pvt. Ltd.

Bangalore, Karnataka, India, 560034

Sponsors and Collaborators

Dr. Reddy's Laboratories Limited

Investigators

• Principal Investigator: Vijayanthi G, MBBS, MD; Lotus Labs Pvt. Ltd.

More Information

• Responsible Party: M.S. Mohan, Dr. Reddy's Laboratories Limited
• ClinicalTrials.gov Identifier: NCT01132222
• Other Study ID Numbers: 431-04
• First Posted: May 27, 2010
• Last Update Posted: June 14, 2010
• Last Verified: June 2010

Keywords provided by Dr. Reddy's Laboratories Limited:

Bioequivalence; Crossover; Ibuprofen and Pseudoephedrine

Additional relevant MeSH terms:

Malnutrition; Nutrition Disorders; Ibuprofen; Pseudoephedrine; Ephedrine; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Analgesics; Sensory System Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Anti-Inflammatory Agents; Antirheumatic Agents; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Bronchodilator Agents; Autonomic Agents; Anti-Asthmatic Agents; Respiratory System Agents; Nasal Decongestants; Vasoconstrictor Agents; Central Nervous System Stimulants; Sympathomimetics; Adrenergic Agents; Neurotransmitter Agents